Core Viewpoint - The company reported a slight increase in revenue for the first three quarters of 2025, but experienced a significant decline in net profit compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters reached 1.433 billion yuan, representing a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders was 442 million yuan, showing a year-on-year decrease of 15.41% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 392 million yuan, down 17.21% year-on-year [1] - Basic earnings per share were reported at 0.495 yuan [1]

Core Viewpoint - Oupeng Vision (300595.SZ) reported its Q3 results, showing a slight increase in revenue but a significant decline in net profit compared to the previous year [1] Financial Performance - The company's revenue for the first three quarters reached 1.43 billion yuan, representing a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders was 442 million yuan, reflecting a year-on-year decrease of 15.41% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 390 million yuan, down 17.21% year-on-year [1]

Core Insights - The company, Opple Vision (300595), reported a slight increase in revenue for the first three quarters of 2025, with total revenue reaching 1.433 billion yuan, representing a year-on-year growth of 0.13% [1] - However, the net profit attributable to the company decreased by 15.41% year-on-year, amounting to 442 million yuan [1] - The decline in net profit was attributed to a decrease in revenue from high-margin hard lenses, while revenue from lower-margin optical products and technical services increased, leading to a lower profit growth rate compared to revenue growth [1] Revenue and Profit Analysis - Revenue for the first three quarters was 1.433 billion yuan, with a year-on-year increase of 0.13% [1] - Net profit attributable to the company was 442 million yuan, showing a year-on-year decline of 15.41% [1] - In the third quarter alone, net profit decreased by 3.1%, which was lower than the revenue growth [1] Cost and Expense Factors - The increase in sales expenses was noted, with a year-on-year rise of 9.75%, and an 8.53% increase in the third quarter [1] - The rise in sales expenses was primarily due to the hiring of additional sales and technical support personnel, as well as promotional activities [1] - Newly established optical terminals generated low initial revenue but incurred high fixed costs, contributing to the increase in revenue without a corresponding increase in profit [1]

Core Viewpoint - The company reported a slight increase in revenue but a significant decline in net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved operating revenue of 1.433 billion yuan, representing a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders was 442 million yuan, showing a year-on-year decrease of 15.41% [1] - Basic earnings per share were 0.4950 yuan, also down by 15.41% year-on-year [1]

证券代码：300595 证券简称：欧普康视 公告编号：2025-085 欧普康视科技股份有限公司 欧普康视科技股份有限公司 董事会 二○二五年十月二十五日 1 2025 年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司 2025 年第三季度报告于 2025 年 10 月 25 日在中 国证监会指定的创业板信息披露媒体巨潮资讯网（http://www.cninfo.com.cn） 上披露，敬请投资者注意查阅。 特此公告。 ...

欧普康视科技股份有限公司 关于软性亲水接触镜获得医疗器械注册证的公告 证券代码：300595 证券简称：欧普康视 公告编号：2025-087 欧普康视科技股份有限公司（以下简称"公司"）的全资子公司欧普康视投 资有限公司的控股子公司江苏多姿医疗科技有限公司（以下简称"多姿医疗"） 于近日收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》（注 册证编号：国械注准 20253162076），多姿医疗的"软性亲水接触镜"新产品已 完成注册并获得第三类医疗器械注册证。现将具体信息公告如下： 一、注册产品基本情况 1、注册人名称：江苏多姿医疗科技有限公司 2、注册人住所：江苏省丹阳市开发区九纬路 1 号 3、生产地址：江苏省丹阳市开发区九纬路 1 号二号楼一层二层、三号楼一 层二层 4、产品名称：软性亲水接触镜 5、注册分类：第三类 6、型号、规格：型号：Rhodos 规格：无 7、结构及组成：该产品为日戴软性亲水接触镜，由 HEMA、NVP、GMMA、EGDMA 及着色剂等聚合而成，着浅蓝色，采用 PP 杯包装。含水量标称值：43%。推荐更 换周期一天。产品经湿热灭菌。货架有效期 5 年。 8、适用范围：日 ...

证券代码：300595 证券简称：欧普康视 公告编号：2025-084 欧普康视科技股份有限公司 第四届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （一）欧普康视科技股份有限公司（以下简称"公司"）第四届董事会第十 九次会议，于 2025 年 10 月 19 日以专人送达、即时通讯等方式发出会议通知。 （四）本次会议由董事长陶悦群先生主持，公司全体高级管理人员列席会议。 （五）本次会议召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经投票表决，会议审议通过如下决议： 以 9 票赞成，0 票反对，0 票弃权审议通过《欧普康视科技股份有限公司 2025 年第三季度报告》 《欧普康视科技股份有限公司 2025 年第三季度报告》编制和审核程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 2025 年第三季度经营的实际情况，不存在虚假记载、误导性陈述或者重大遗漏。 公司董事会审计委员会已审议通过本议案并同意提交董事会审议。具体内容 详见公司同日在巨潮资讯网（ht ...

Core Viewpoint - The company has successfully registered a new product, a daily wear soft hydrophilic contact lens, which has received a Class III medical device registration certificate [1] Product Details - The new product is composed of HEMA, NVP, GMMA, EGDMA, and coloring agents, and is packaged in a light blue PP cup [1] - The lens has a nominal water content of 43% and is recommended for daily replacement [1] - The product undergoes moist heat sterilization and has a shelf life of 5 years [1] - It is intended for daily wear to correct myopia in patients without contraindications [1] - The registration certificate number is 国械注准20253162076, valid until October 20, 2030 [1]

Financial Performance - The company's revenue for Q3 2025 was ¥562,095,281.42, representing a 2.62% increase year-over-year[5] - The net profit attributable to shareholders for Q3 2025 was ¥192,052,456.69, a decrease of 3.10% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2025 was ¥175,553,233.68, down 7.70% year-over-year[5] - For the first three quarters of 2025, total revenue reached ¥1,432,791,310.58, a slight increase of 0.13% compared to the previous year[10] - The net profit attributable to shareholders for the first three quarters of 2025 was ¥442,049,628.72, reflecting a decline of 15.41% year-over-year[10] - Total revenue for the current period reached ¥1,432,791,310.58, slightly up from ¥1,430,989,125.43 in the previous period, indicating a growth of approximately 0.1%[38] - The total profit for the current period is approximately ¥579.55 million, a decrease from ¥666.50 million in the previous period, representing a decline of about 13.06%[39] - The net profit attributable to shareholders of the parent company is ¥442.05 million, down from ¥522.58 million, reflecting a decrease of approximately 15.38%[39] - Basic and diluted earnings per share are both ¥0.4950, down from ¥0.5852, reflecting a decrease of about 15.99%[39] Assets and Liabilities - The total assets at the end of Q3 2025 were ¥6,424,704,230.26, an increase of 6.53% from the end of the previous year[5] - Current assets totaled ¥3,930,608,517.36, up from ¥3,786,642,193.57, marking an increase of about 3.8%[34] - Non-current assets increased to ¥2,494,095,712.90 from ¥2,244,259,250.58, showing a growth of approximately 11.1%[35] - Total liabilities rose to ¥994,265,312.13 from ¥887,237,280.20, reflecting an increase of approximately 12.1%[35] - Shareholders' equity increased to ¥5,430,438,918.13 from ¥5,143,664,163.95, representing a growth of about 5.6%[36] Expenses - The company experienced a 9.75% increase in sales expenses year-over-year, impacting overall profitability[15] - Management expenses increased by 30.43% to ¥92,932,807.31, mainly due to a year-on-year increase in share-based payment expenses[21] - Financial expenses surged by 92.89% to ¥9,490,828.46, primarily due to a decrease in bank deposit interest income[21] - Total operating costs increased to ¥904,982,197.64 from ¥818,680,422.69, representing a rise of about 10.5%[38] - Research and development expenses for the current period were ¥33,003,853.59, compared to ¥30,458,497.52 in the previous period, indicating an increase of approximately 8.4%[38] Cash Flow - Operating cash inflows increased by 1.99% to ¥1,553,084,830.29, while operating cash outflows rose by 4.92% to ¥978,367,348.02[24] - The operating cash flow for the current period is ¥574.72 million, slightly down from ¥590.25 million, indicating a decrease of about 2.93%[41] - The total cash inflow from investment activities is ¥3.86 billion, compared to ¥2.46 billion in the previous period, showing an increase of approximately 56.73%[41] - The net cash flow from financing activities is -¥458.76 million, worsening from -¥282.54 million in the previous period, indicating a decline of about 62.38%[42] - Cash and cash equivalents at the end of the period were ¥773,689,250.75, up from ¥758,365,298.49, reflecting a growth of about 2.0%[34] - The cash and cash equivalents at the end of the period amount to ¥770.96 million, down from ¥923.77 million, indicating a decrease of approximately 16.46%[42] Shareholder Information - The total number of common shareholders at the end of the reporting period was 60,704[26] - The largest shareholder, Tao Yuequn, holds 33.35% of the shares, totaling 298,890,828 shares[26] - The top shareholder, Nanjing Otao Information Technology Co., Ltd., holds 100,464,421 shares, representing a significant portion of the company's equity[27] - The second-largest shareholder, Tao Yuequn, owns 74,722,707 shares, indicating a strong individual stake in the company[27] - The total number of shares held by the top 10 shareholders includes 15,241,012 shares from China Bank Co., Ltd. - Huabao CSI Medical ETF[27] - The company has a total of 224,168,121 restricted shares held by Tao Yuequn, which are subject to lock-up agreements[29] - The number of restricted shares for Fu Zhiying decreased by 25,000 shares, leaving a total of 358,352 shares under lock-up[29] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[28] - There are no new restricted shares added during the reporting period, maintaining the current total[29] - The company has not disclosed any relationships or concerted actions among the top shareholders[27] - The total number of shares held by the top 10 unrestricted shareholders is 10,906,381 shares from the E Fund ChiNext ETF[27] - The company has not applied for any changes in the status of preferred shareholders or restricted shares[28] - The total number of shares for the company is 228,182,912, with 525,286 shares available for sale and 227,657,626 shares under lock-up[31] - The company has implemented various equity incentive plans with different lock-up periods ranging from 12 months to 60 months[30] - The total number of shares under other equity incentives is 2,794,887, with 373,786 shares available for sale[31] - The company has a total of 125,000 shares allocated for key personnel, with 100,000 shares under lock-up[30] - The company reported a significant number of shares under various incentive plans, indicating a strong commitment to employee retention and motivation[31] - The equity incentive plans are designed to incentivize performance and align with the company's long-term objectives[30] Market Strategy - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[32] - The company is actively managing its share structure to optimize shareholder value and support future growth strategies[32] - The company is committed to transparency in its financial reporting and shareholder communications[32] Audit Information - The company has not undergone an audit for the third quarter financial report[43]

Core Viewpoint - The company, Opcon Vision, has received a new medical device production license from the Anhui Provincial Drug Administration, indicating an expansion in its production capabilities and product range [2]. Group 1: License Update - The company has completed the change registration for its medical device production license [2]. - The new license includes an additional production address located at "No. 1, 1st Floor, Building C, 4899 Wangjiang West Road, High-tech Zone, Hefei" [2]. - The production scope has been expanded to include "08-05 respiratory, anesthesia, and emergency device auxiliary equipment" [2].